



TRICARE Formulary Fact Sheet

TRICARE Uniform Formulary Coverage Information and Prior Authorization Request Form for ORGOVYX

Updated January 2026

The formulary coverage information and prior authorization (PA) form were developed independently by TRICARE. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by TRICARE. Sumitomo Pharma America, Inc. and Pfizer, Inc. did not influence the coverage determination or the development of the PA form by TRICARE.

- Any questions related to this content should be directed to TRICARE
- Sumitomo Pharma America, Inc. and Pfizer Inc. recommend use of ORGOVYX only as contained in the ORGOVYX **Prescribing Information**
- Follow the instructions on page 2 to access the PA criteria from the TRICARE Formulary Search Tool website

Criteria are subject to be changed/updated. Please visit the TRICARE Formulary Search Tool website for the most up-to-date information.

Please see Important Safety Information on page 5 and accompanying full [Prescribing Information](#) for ORGOVYX.



IS COVERED ON TRICARE TIER 2 UNIFORM FORMULARY WITH PRIOR AUTHORIZATION (PA)^{1,2}

Each bottle contains 30 tablets. NDC: 72974-120-01

Tablet not shown at actual size. Actual tablet size: 10.7 mm x 7.5 mm x 5.2 mm.³

PHARMACY	COVERAGE	COPAY	HOW TO ORDER
Military (MTF) Up to 90-day supply	Tier 2 uniform formulary coverage rules apply PA required	\$0*	 Scan here
Home Delivery Up to 90-day supply	Tier 2 uniform formulary coverage rules apply PA required	\$44†	
Accredo provides specialty pharmacy services through TRICARE Pharmacy Home Delivery . Outside of TRICARE Pharmacy Home Delivery, payer-affiliated specialty pharmacies do not have access to ORGOVYX.			
Retail Up to 30-day supply	Tier 2 uniform formulary coverage rules apply PA required	\$48†	

*\$0 copay applies at military point of service if PA is approved.

[†]\$0 copay applies to active duty at any point of service if PA is approved.



Scan the QR code to access the TRICARE Prior Authorization Request Form for ORGOVYX

Criteria are subject to be changed/updated. Please visit the TRICARE Formulary Search Tool website for the most up-to-date information.

This website is neither owned nor controlled by SMPA and Pfizer. SMPA and Pfizer are not responsible for the content or services of this site.

INDICATION and IMPORTANT SAFETY INFORMATION

INDICATION

ORGOVYX® (relugolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer.

IMPORTANT SAFETY INFORMATION

Contraindication

ORGOVYX is contraindicated in patients with severe hypersensitivity to relugolix or to any of the product components.

Warnings and Precautions

QT/QTc Interval Prolongation: Androgen deprivation therapy, such as ORGOVYX may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, or frequent electrolyte abnormalities and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes.

Hypersensitivity: Angioedema was reported in 0.2% of patients treated with ORGOVYX in HERO. Hypersensitivity reactions, including pharyngeal edema and other serious cases of angioedema, have been reported post-marketing with ORGOVYX. Advise patients who experience any symptoms of hypersensitivity to temporarily discontinue ORGOVYX and promptly seek medical care. Discontinue ORGOVYX for severe hypersensitivity reactions and manage as clinically indicated.

Embryo-Fetal Toxicity: The safety and efficacy of ORGOVYX have not been established in females. Based on findings in animals and mechanism of action, ORGOVYX can cause fetal harm and loss of pregnancy when administered to a pregnant female. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 2 weeks after the last dose of ORGOVYX.

Laboratory Testing: Therapy with ORGOVYX results in suppression of the pituitary gonadal system. Results of diagnostic tests of the pituitary gonadotropic and gonadal functions conducted during and after ORGOVYX may be affected. The therapeutic effect of ORGOVYX should be monitored by measuring serum concentrations of prostate-specific antigen (PSA) periodically. If PSA increases, serum concentrations of testosterone should be measured.

Adverse Reactions

Serious adverse reactions occurred in 12% of patients receiving ORGOVYX. Serious adverse reactions in $\geq 0.5\%$ of patients included myocardial infarction (0.8%), acute kidney injury (0.6%), arrhythmia (0.6%), hemorrhage (0.6%), and urinary tract infection (0.5%). Fatal adverse reactions occurred in 0.8% of patients receiving ORGOVYX including metastatic lung cancer (0.3%), myocardial infarction (0.3%), and acute kidney injury (0.2%). Fatal and non-fatal myocardial infarction and stroke were reported in 2.7% of patients receiving ORGOVYX.

Most common adverse reactions ($\geq 10\%$) and laboratory abnormalities ($\geq 15\%$) in patients receiving ORGOVYX were hot flush (54%), glucose increased (44%), triglycerides increased (35%), musculoskeletal pain (30%), hemoglobin decreased (28%), alanine aminotransferase increased (27%), fatigue (26%), aspartate aminotransferase increased (18%), constipation (12%), and diarrhea (12%).

Drug Interactions

Co-administration of ORGOVYX with an oral P-gp inhibitor increases relugolix exposure, which may increase the risk of adverse reactions associated with ORGOVYX. Avoid co-administration of ORGOVYX with oral P-gp inhibitors. If co-administration is unavoidable, take ORGOVYX first and separate dosing by at least 6 hours. Monitor patients for increased adverse reactions. Treatment with ORGOVYX may be interrupted for up to 2 weeks if a short course of treatment with a P-gp inhibitor is required. Resume ORGOVYX after the P-gp inhibitor is discontinued. If treatment with ORGOVYX is interrupted for greater than 7 days, restart ORGOVYX with a 360 mg loading dose on the first day and continue with 120 mg once daily.

Co-administration of ORGOVYX with a combined P-gp and strong CYP3A inducer decreases relugolix exposure, which may reduce the effects of ORGOVYX. Avoid co-administration of ORGOVYX with combined P-gp and strong CYP3A inducers. If co-administration is unavoidable, increase the ORGOVYX dose to 240 mg once daily. After discontinuation of the combined P-gp and strong CYP3A inducer, resume the recommended ORGOVYX dose of 120 mg once daily.

Please see accompanying full [Prescribing Information](#) for ORGOVYX.

References: 1. Express Scripts. TRICARE formulary search tool. Accessed January 2026. www.express-scripts.com. <https://www.express-scripts.com/frontend/open-enrollment/tricare/fst/#/formularyPricing/results>
2. TRICARE. Pharmacy costs. Updated November 7, 2025. Accessed November 14, 2025. <https://tricare.mil/Costs/PharmacyCosts>
3. Data on file. Sumitomo Pharma America, Inc.

ORGOVYX®
(relugolix) 120 mg tablets

ORGOVYX[®]

(relugolix) 120 mg tablets



✿ is a trademark of Sumitomo Pharma Co., Ltd., used under license.

SUMITOMO PHARMA is a trademark of Sumitomo Pharma Co., Ltd., used under license.

SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license.

Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co. Ltd.

ORGOVYX[®] and its logo are registered trademarks of Sumitomo Pharma Co. Ltd., used under license.

All other trademarks are the property of their respective owners.

© 2026 Sumitomo Pharma America, Inc. and Pfizer Inc. All rights reserved. ORG-US-0333-25 01/26